Antidepression of Xingpijieyu formula targets gut microbiota derived from depressive disorder

Abstract

XPJYF treatment targets inflammation, activation, and glycometabolim in astrocyte via gut microbiota modulation, thereby improve animal behaviors, HPA axis dysfunction, and neurotransmitter synthesis in depression rats.